StreetInsider.com News Articles

Nuwellis to hold advisory board meeting for pediatric CRRT system

Thu, 08 Oct 2026 08:31:15 -0400

Nuwellis, Inc. (Nasdaq: NUWE) announced it will convene a Medical & Nursing Advisory Board on Nov. 18–19, 2026, to support development of its Vivian pediatric continuous renal replacement therapy (CRRT) system.

The meeting will bring together approximately a dozen pediatric providers, nurses, and clinical advisors from 11 pediatric institutions across the U.S. for a hands-on evaluation of the Vivian system. According to the company, this marks its first dedicated Vivian Medical & Nursing Advisory Board in several years.

The Vivian system is under development for children as small as 2.5 kilograms and is designed to incorporate multiple fluid management therapies in a

Nuwellis to Convene Pediatric Medical & Nursing Advisory Board to Advance Development of Vivian™ Pediatric CRRT System

Thu, 08 Oct 2026 08:30:00 -0400

MINNEAPOLIS, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced that it will convene a Medical & Nursing Advisory Board on November 18–19, 2026, to support the continued development of Vivian™, the Company’s next-generation pediatric continuous renal replacement therapy (CRRT) platform. Vivian is under development for children as small as 2.5kg and it incorporates multiple fluid management therapies in one platform.

“Vivian is being purpose-built around the unique clinical and operational needs of pediatric patients and the clinicians who care for

Nuwellis to Convene Pediatric Medical & Nursing Advisory Board to Advance Development of Vivian™ Pediatric CRRT System

Thu, 08 Oct 2026 08:30:00 -0400

“Vivian is being purpose-built around the unique clinical and operational needs of pediatric patients and the clinicians who care for

Nuwellis to Highlight Advancements in Fluid Management Across Pediatric Care, Critical Care, and Heart Failure at Leading October Medical Conferences

Thu, 01 Oct 2026 08:30:00 -0400

MINNEAPOLIS, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced its participation in four leading medical conferences in October spanning pediatrics, critical care, and heart failure. Across the events, Nuwellis will engage directly with clinicians on the challenge of fluid overload and the role of its Aquadex SmartFlow® system in providing precise, controlled fluid removal for patients who require individualized fluid management.

“Pediatrics, critical care, and heart failure are the three key growth markets for Nuwellis, and fluid overload is a

Nuwellis to Highlight Advancements in Fluid Management Across Pediatric Care, Critical Care, and Heart Failure at Leading October Medical Conferences

Thu, 01 Oct 2026 08:30:00 -0400

“Pediatrics, critical care, and heart failure are the three key growth markets for Nuwellis, and fluid overload is a

Form SCHEDULE 13G/A Nuwellis, Inc. Filed by: Orca Capital AG

Fri, 18 Sep 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260918/27081189.html

Nuwellis sells 31 Aquadex consoles year-to-date in 2026

Thu, 17 Sep 2026 08:31:41 -0400

Nuwellis, Inc. (Nasdaq: NUWE) reported that it has sold 31 Aquadex SmartFlow consoles year-to-date in 2026, a figure the company says already exceeds full-year console sales in seven of the past 10 years, according to a press release.

The Minneapolis-based medical technology company also reported 26% year-over-year U.S. revenue growth during the first half of 2026, with gains across its pediatric, critical-care, and heart-failure segments.

The Aquadex SmartFlow system consists of a console, catheter, and disposable blood circuit set used to deliver ultrafiltration therapy. Each console placement generates recurring revenue through the use of single-use blood circuits.

"Selling 31 consoles at this point

Nuwellis Reports Strong Aquadex Console Adoption, with 31 Aquadex SmartFlow Consoles Sold Year-to-Date, Meaningfully Expanding Recurring Revenue Opportunity

Thu, 17 Sep 2026 08:30:00 -0400

MINNEAPOLIS, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced continued commercial momentum for its Aquadex SmartFlow® system, with 31 consoles sold year-to-date in 2026. The Company's year-to-date console performance already exceeds full-year console sales in seven of the past 10 years and puts Nuwellis on pace for one of its top three years for console sales. The expanding installed base comes alongside broader commercial momentum, including 26% year-over-year U.S. revenue growth during the first half of 2026.

“Selling 31

Nuwellis Reports Strong Aquadex Console Adoption, with 31 Aquadex SmartFlow Consoles Sold Year-to-Date, Meaningfully Expanding Recurring Revenue Opportunity

Thu, 17 Sep 2026 08:30:00 -0400

“Selling 31

Nuwellis names Brian Johnson as director of quality and regulatory

Wed, 16 Sep 2026 08:30:34 -0400

Nuwellis, Inc. (Nasdaq: NUWE) has appointed Brian Johnson as Director of Quality and Regulatory Affairs, according to a company statement.

Johnson brings 13 years of medical device quality and regulatory experience. He previously served as Senior Quality Manager at Baxter/Vantive, where he provided quality oversight for two research and development facilities supporting 257 engineering and management employees. Before that, he held quality leadership roles at ATL Medical, where he helped reduce monthly customer complaints by 80%.

Johnson holds a Master of Science in Regulatory Affairs and Services from St. Cloud State University and a Bachelor of Science in Manufacturing Engineering Technology from

Nuwellis Strengthens Organization with Appointment of Brian Johnson as Director of Quality and Regulatory Affairs

Wed, 16 Sep 2026 08:30:00 -0400

MINNEAPOLIS, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of Brian Johnson as Director of Quality and Regulatory Affairs. Johnson brings 13 years of medical device quality and regulatory experience, with a proven track record leading quality systems, regulatory activities, audits and product development initiatives. His appointment strengthens Nuwellis' quality and regulatory capabilities as the Company continues to invest in the expertise needed to advance product development, commercialization and initiatives across the cardiorenal continuum.

"Brian's experience

Nuwellis Strengthens Organization with Appointment of Brian Johnson as Director of Quality and Regulatory Affairs

Wed, 16 Sep 2026 08:30:00 -0400

"Brian's experience

Nuwellis reports gross margin rise to 76% in Q2 2026

Wed, 09 Sep 2026 08:33:31 -0400

Nuwellis, Inc. (NASDAQ: NUWE), a medical technology company focused on cardiorenal conditions, reported a gross margin of 76% for the second quarter of 2026, up from 56% in the same period a year earlier, according to a company statement.

The improvement follows the company's transition of Aquadex product manufacturing to KDI Manufacturing, a contract manufacturer, which began approximately one year ago. Since the transition, KDI Manufacturing has delivered nearly 5,000 AquaFlexFlow blood circuits and 30 Aquadex SmartFlow consoles, and has serviced more than 200 consoles. The company said finished goods have continued to pass quality inspections at rates comparable to those

Form EFFECT Nuwellis, Inc.

Thu, 27 Aug 2026 06:07:00 -0400

si-local-file:///var/storage/secattach/20260827/26984176.html

Form EFFECT Nuwellis, Inc.

Thu, 27 Aug 2026 06:07:00 -0400

si-local-file:///var/storage/secattach/20260827/26984176.html

Form 424B3 Nuwellis, Inc.

Wed, 26 Aug 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260826/26982814.html

Form 424B3 Nuwellis, Inc.

Wed, 26 Aug 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260826/26982814.html

Form 8-K Nuwellis, Inc. For: Aug 25

Wed, 26 Aug 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260826/26976825.html

Form 8-K Nuwellis, Inc. For: Aug 25

Wed, 26 Aug 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260826/26976825.html

Nuwellis strikes co-promotion deal with Atrility Medical for AtriAmp

Tue, 25 Aug 2026 08:32:34 -0400

Nuwellis, Inc. (NASDAQ: NUWE) and Atrility Medical, Inc. have entered into a co-promotion and distribution agreement for Atrility's AtriAmp device, the companies announced.

Under the agreement, the two companies will begin a six-month co-promotion program covering three Nuwellis sales territories across approximately nine Western and five Southeastern states. Nuwellis will receive commissions on sales to existing and new customers within those territories. Atrility will continue to serve its existing customers in the covered areas while Nuwellis pursues new customer relationships.

If the pilot program is completed successfully, Nuwellis is expected to transition to Atrility's exclusive U.S. distributor for much of the country,

Nuwellis Expands Critical Care Portfolio Through Strategic Commercial Agreement with Atrility Medical

Tue, 25 Aug 2026 08:30:00 -0400

MINNEAPOLIS and MADISON, Wis., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, and Atrility Medical, Inc, a cardiac medical technology company, today announced that they have entered into a co-promotion and distribution agreement for Atrility’s AtriAmp® device.

“AtriAmp is an excellent strategic fit with Nuwellis' growing pediatric and critical care portfolio, serving many of the same hospitals, physicians and care teams that our commercial organization supports today,” said Mike McCormick, Nuwellis President and Chief Executive Officer. “This staged agreement is

Nuwellis Expands Critical Care Portfolio Through Strategic Commercial Agreement with Atrility Medical

Tue, 25 Aug 2026 08:30:00 -0400

Nuwellis Expands Critical Care Portfolio Through Strategic Commercial Agreement with Atrility Medical

Tue, 25 Aug 2026 08:30:00 -0400

Nuwellis Expands Critical Care Portfolio Through Strategic Commercial Agreement with Atrility Medical

Tue, 25 Aug 2026 08:30:00 -0400

Form S-3 Nuwellis, Inc.

Tue, 18 Aug 2026 16:42:00 -0400

si-local-file:///var/storage/secattach/20260818/26944996.html